Xiaoding Hu

554 total citations
23 papers, 402 citations indexed

About

Xiaoding Hu is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiaoding Hu has authored 23 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Xiaoding Hu's work include Systemic Sclerosis and Related Diseases (3 papers), DNA Repair Mechanisms (3 papers) and Connective Tissue Growth Factor Research (3 papers). Xiaoding Hu is often cited by papers focused on Systemic Sclerosis and Related Diseases (3 papers), DNA Repair Mechanisms (3 papers) and Connective Tissue Growth Factor Research (3 papers). Xiaoding Hu collaborates with scholars based in United States, China and France. Xiaoding Hu's co-authors include Jiaxue Wu, Bisrat G. Debeb, Emilly S. Villodre, J Wang, Wendy A. Woodward, Naoto T. Ueno, Debu Tripathy, Long Yu, Juhee Song and Yun Gong and has published in prestigious journals such as PLoS ONE, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Xiaoding Hu

23 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoding Hu United States 13 284 132 109 91 40 23 402
Isabel Soria‐Bretones Canada 9 293 1.0× 126 1.0× 84 0.8× 66 0.7× 57 1.4× 10 378
Shoujie Chai China 10 239 0.8× 204 1.5× 143 1.3× 109 1.2× 47 1.2× 12 431
Nicola Inzerilli Italy 5 302 1.1× 99 0.8× 120 1.1× 77 0.8× 19 0.5× 8 420
Jinwei Hao Australia 3 255 0.9× 197 1.5× 129 1.2× 92 1.0× 41 1.0× 3 432
Chengyong Lei China 11 294 1.0× 94 0.7× 136 1.2× 74 0.8× 43 1.1× 18 433
Gaoda Ju China 9 252 0.9× 109 0.8× 150 1.4× 118 1.3× 37 0.9× 20 391
Jugang Wu China 16 237 0.8× 197 1.5× 99 0.9× 156 1.7× 29 0.7× 30 518
Lufeng Liang China 14 268 0.9× 126 1.0× 130 1.2× 64 0.7× 72 1.8× 20 469
Bi‐Jun Huang China 10 248 0.9× 106 0.8× 126 1.2× 75 0.8× 44 1.1× 36 382
Zijie Cai China 7 286 1.0× 145 1.1× 194 1.8× 101 1.1× 21 0.5× 9 471

Countries citing papers authored by Xiaoding Hu

Since Specialization
Citations

This map shows the geographic impact of Xiaoding Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoding Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoding Hu more than expected).

Fields of papers citing papers by Xiaoding Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoding Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoding Hu. The network helps show where Xiaoding Hu may publish in the future.

Co-authorship network of co-authors of Xiaoding Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoding Hu. A scholar is included among the top collaborators of Xiaoding Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoding Hu. Xiaoding Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yin, Ling, Xiaoding Hu, Guangsheng Pei, et al.. (2024). Genome-wide CRISPR screen reveals the synthetic lethality between BCL2L1 inhibition and radiotherapy. Life Science Alliance. 7(4). e202302353–e202302353. 4 indexed citations
2.
Hu, Xiaoding, Yun Xiong, Emilly S. Villodre, et al.. (2023). Abstract GS5-08: Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. Cancer Research. 83(5_Supplement). GS5–8. 1 indexed citations
3.
Villodre, Emilly S., Xiaoding Hu, Richard Larson, et al.. (2021). Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology. 15(10). 2752–2765. 27 indexed citations
4.
Fukumura, Kazutaka, Prit Benny Malgulwar, Grant M. Fischer, et al.. (2021). Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathologica. 141(2). 303–321. 32 indexed citations
5.
Hu, Xiaoding, Emilly S. Villodre, Richard Larson, et al.. (2021). Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Communications Biology. 4(1). 72–72. 50 indexed citations
6.
Hu, Xiaoding, Emilly S. Villodre, Wendy A. Woodward, & Bisrat G. Debeb. (2021). Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells. Journal of Visualized Experiments. 4 indexed citations
7.
Liu, Wenli, et al.. (2021). ZFPM2‐AS1 facilitates cell proliferation and migration in cutaneous malignant melanoma through modulating miR‐650/NOTCH1 signaling. Dermatologic Therapy. 34(2). e14751–e14751. 14 indexed citations
8.
Hu, Xiaoding, Emilly S. Villodre, Richard Larson, et al.. (2020). Abstract P3-01-06: Decorin-mediated suppression of tumorigenesis and skin invasion in inflammatory breast cancer via inhibition of the E-cadherin/EGFR axis. Cancer Research. 80(4_Supplement). P3–1. 1 indexed citations
9.
Villodre, Emilly S., Yun Gong, Xiaoding Hu, et al.. (2020). NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers. 12(12). 3711–3711. 23 indexed citations
10.
Villodre, Emilly S., Xiaoding Hu, Richard Larson, et al.. (2020). Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis. Cancer Research. 80(4_Supplement). P3–1. 3 indexed citations
11.
Hu, Xiaoding, Li Wei, Dan Song, et al.. (2018). PARP10 suppresses tumor metastasis through regulation of Aurora A activity. Oncogene. 37(22). 2921–2935. 41 indexed citations
12.
Song, Dan, Huixing Huang, J Wang, et al.. (2017). NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 488(1). 211–217. 27 indexed citations
13.
Zhu, Bo, Xiaoding Hu, Xiaofeng Jin, et al.. (2017). Knockout of the Nogo-B Gene Attenuates Tumor Growth and Metastasis in Hepatocellular Carcinoma. Neoplasia. 19(7). 583–593. 26 indexed citations
14.
Hu, Xiaoding, Yan Zhao, Luyao Wei, et al.. (2017). CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis. Oncogene. 36(28). 4047–4059. 39 indexed citations
15.
Ahmed, Zamal, Cristina Ivan, Jonathan Berrout, et al.. (2015). Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. 35(17). 2186–2196. 26 indexed citations
16.
Jin, Xiaofeng, et al.. (2015). Glaucocalyxin A inhibits the growth of liver cancer Focus and SMMC-7721 cells. Oncology Letters. 11(2). 1173–1178. 13 indexed citations
17.
18.
Liu, Tong & Xiaoding Hu. (2011). [Transdifferentiation of fibroblasts into myofibroblasts in the skin lesion of systemic sclerosis: role of transforming growth factor β1 and its signal transduction].. PubMed. 31(11). 1840–5. 1 indexed citations
19.
Hu, Xiaoding, Xiping Xu, Joseph Ragaz, et al.. (2009). PP16 Metronomic weekly use of zoledronic acid for breast cancer with bone metastases has more potent antitumor and bone-preserving effects than conventional zoledronic acid given every-four-weeks. European Journal of Cancer Supplements. 7(4). 19–20. 1 indexed citations
20.
Pan, C., Xiaoding Hu, & Jun‐Fang Lin. (1999). TEMPORAL FLUCTUATIONS IN MELOIDOGYNE FUJIANENSIS PARASITIZING CITRUS RETICULATA IN NANJING, CHINA. Nematologia mediterranea. 27(2). 327–330. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabel Soria‐Bretones Breakdown of academic impact, for papers by Shoujie Chai Breakdown of academic impact, for papers by Nicola Inzerilli Breakdown of academic impact, for papers by Jinwei Hao Breakdown of academic impact, for papers by Chengyong Lei Breakdown of academic impact, for papers by Gaoda Ju Breakdown of academic impact, for papers by Jugang Wu Breakdown of academic impact, for papers by Lufeng Liang Breakdown of academic impact, for papers by Bi‐Jun Huang Breakdown of academic impact, for papers by Zijie Cai
Rankless by CCL
2026